ZIDOVUDINE COMBINATION THERAPIES FOR TREATING MICROBIAL INFECTIONS

(19)

(11)

EP 3 099 298 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	22.05.2019 Bulletin 2019/21

(45)	Mention of the grant of the patent:
	20.03.2019 Bulletin 2019/12

(21)	Application number: 15704827.3

(22)	Date of filing: 29.01.2015

(51)

International Patent Classification (IPC):

A61K 31/435^(2006.01)
A61K 31/496^(2006.01)
A61K 38/12^(2006.01)
A61P 31/10^(2006.01)

A61K 31/4525^(2006.01)
A61K 31/7072^(2006.01)
A61P 31/04^(2006.01)

(86)	International application number:
	PCT/GB2015/050209

(87)	International publication number:
	WO 2015/114340 (06.08.2015 Gazette 2015/31)

(54)	ZIDOVUDINE COMBINATION THERAPIES FOR TREATING MICROBIAL INFECTIONS ZIDOVUDINKOMBINATIONSTHERAPIEN ZUR BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN THÉRAPIES COMBINATOIRES PAR ZIDOVUDINE POUR LE TRAITEMENT D'INFECTIONS MICROBIENNES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

30.01.2014 GB 201401617

(43)	Date of publication of application:
	07.12.2016 Bulletin 2016/49

(73)	Proprietor: Helperby Therapeutics Limited
	London WC2A 3LH (GB)

(72)	Inventors:
	COATES, Anthony London SW17 0RE (GB) HU, Yanmin London SW17 0RE (GB)

(74)	Representative: D Young & Co LLP
	120 Holborn London EC1N 2DY London EC1N 2DY (GB)

(56)

References cited: :

WO-A1-2007/054599

PANTOPOULOU ET AL: "Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 29, no. 1, 22 December 2006 (2006-12-22), pages 51-55, XP005812322, ISSN: 0924-8579, DOI: 10.1016/J.IJANTIMICAG.2006.09.009
B R KEITH ET AL: "In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 33, no. 4, April 1989 (1989-04), pages 479-483, XP055179911, ISSN: 0066-4804, DOI: 10.1128/AAC.33.4.479
DOLÉANS-JORDHEIM A ET AL: "Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains", EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, SPRINGER, BERLIN, DE, vol. 30, no. 10, 15 April 2011 (2011-04-15), pages 1249-1256, XP019951616, ISSN: 1435-4373, DOI: 10.1007/S10096-011-1220-3 cited in the application
MASCELLINO M T ET AL: "In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 7, no. 1, June 1993 (1993-06), pages 23-28, XP023924467, ISSN: 0928-8244, DOI: 10.1111/J.1574-695X.1993.TB00377.X [retrieved on 1993-06-01]
E TAGLIAFERRI ET AL: "Synergistic Activity of Colistin (COL) plus Rifampin (RIF) Against COL-Resistant (R) and Susceptible (S) KPC-producing Klebsiella pneumoniae (KPC-KP) clinical isolates", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, September 2012 (2012-09), page E796, XP055151648,
CHITNIS S ET AL: "In vitro synergistic activity of colistin with aminoglycosides, beta-lactams and rifampin against multidrug-resistant gram-negative bacteria", JOURNAL OF CHEMOTHERAPY, SCRIT, IT, vol. 19, no. 2, April 2007 (2007-04), pages 226-229, XP009169446, ISSN: 1120-009X
R. K. BHARDWAJ: "Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 302, no. 2, August 2002 (2002-08), pages 645-650, XP055180107, ISSN: 0022-3565, DOI: 10.1124/jpet.102.034728 cited in the application

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).